Bank of Montreal Can Trims Stock Holdings in Edwards Lifesciences Corporation $EW

Bank of Montreal Can decreased its position in Edwards Lifesciences Corporation (NYSE:EW) by 16.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 684,898 shares of the medical research company’s stock after selling 136,956 shares during the period. Bank of Montreal Can’s holdings in Edwards Lifesciences were worth $53,566,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Burney Co. purchased a new position in Edwards Lifesciences in the 2nd quarter worth $2,857,000. W.G. Shaheen & Associates DBA Whitney & Co raised its stake in shares of Edwards Lifesciences by 0.9% during the 2nd quarter. W.G. Shaheen & Associates DBA Whitney & Co now owns 168,173 shares of the medical research company’s stock valued at $13,153,000 after buying an additional 1,498 shares during the last quarter. Telos Capital Management Inc. raised its stake in shares of Edwards Lifesciences by 12.9% during the 2nd quarter. Telos Capital Management Inc. now owns 62,415 shares of the medical research company’s stock valued at $4,881,000 after buying an additional 7,156 shares during the last quarter. Mission Wealth Management LP raised its stake in shares of Edwards Lifesciences by 2.4% during the 2nd quarter. Mission Wealth Management LP now owns 45,530 shares of the medical research company’s stock valued at $3,561,000 after buying an additional 1,073 shares during the last quarter. Finally, Versor Investments LP raised its stake in shares of Edwards Lifesciences by 15.2% during the 2nd quarter. Versor Investments LP now owns 17,857 shares of the medical research company’s stock valued at $1,397,000 after buying an additional 2,357 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of the business’s stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the sale, the insider directly owned 206,900 shares in the company, valued at approximately $16,150,614. The trade was a 4.15% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of Edwards Lifesciences stock opened at $82.86 on Thursday. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a twelve month low of $64.89 and a twelve month high of $87.09. The business has a 50-day moving average price of $77.72 and a 200 day moving average price of $77.18. The firm has a market cap of $48.65 billion, a PE ratio of 11.92, a P/E/G ratio of 3.97 and a beta of 1.03.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company had revenue of $1.55 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same period in the previous year, the business earned $0.67 EPS. Edwards Lifesciences’s quarterly revenue was up 14.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. Sell-side analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on EW. Wall Street Zen lowered Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a research note on Monday, September 29th. Canaccord Genuity Group reiterated a “hold” rating and set a $84.00 price objective (up previously from $81.00) on shares of Edwards Lifesciences in a research note on Monday. Jefferies Financial Group set a $98.00 price objective on Edwards Lifesciences and gave the company a “buy” rating in a research note on Wednesday, October 29th. Morgan Stanley lifted their price objective on Edwards Lifesciences from $75.00 to $81.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 15th. Finally, The Goldman Sachs Group set a $104.00 price objective on Edwards Lifesciences and gave the company a “buy” rating in a research note on Friday, October 31st. Three research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $91.39.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.